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MaBACKGROUND Recently, tangles and plaque-like aggregates have been identiﬁed in certain cases of dilated cardio-
myopathy (DCM), traditionally labeled idiopathic (iDCM), where there is no speciﬁc diagnostic test or targeted therapy.
This suggests a potential underlying cause for some of the iDCM cases.
OBJECTIVES This study sought to identify the make-up of myocardial aggregates to understand the molecular
mechanisms of these cases of DCM; this strategy has been central to understanding Alzheimer’s disease.
METHODS Aggregates were extracted from human iDCM samples with high congophilic reactivity (an indication of
plaque presence), and the ﬁndings were validated in a larger cohort of samples. We tested the expression, distribution,
and activity of coﬁlin in human tissue and generated a cardiac-speciﬁc knockout mouse model to investigate the
functional impact of the human ﬁndings. We also modeled coﬁlin inactivity in vitro by using pharmacological and genetic
gain- and loss-of-function approaches.
RESULTS Aggregates in human myocardium were enriched for coﬁlin-2, an actin-depolymerizing protein known
to participate in neurodegenerative diseases and nemaline myopathy. Coﬁlin-2 was predominantly phosphorylated,
rendering it inactive. Cardiac-speciﬁc haploinsufﬁciency of coﬁlin-2 in mice recapitulated the human disease’s morpho-
logical, functional, and structural phenotype. Pharmacological stimulation of coﬁlin-2 phosphorylation and genetic
overexpression of the phosphomimetic protein promoted the accumulation of “stress-like” ﬁbers and severely impaired
cardiomyocyte contractility.
CONCLUSIONS Our study provides the ﬁrst biochemical characterization of preﬁbrillar myocardial aggregates in
humans and the ﬁrst report to link coﬁlin-2 to cardiomyopathy. The ﬁndings suggest a common pathogenetic mechanism
connecting certain iDCMs and other chronic degenerative diseases, laying the groundwork for new therapeutic strategies.
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ABBR EV I A T I ON S
AND ACRONYMS
AD = Alzheimer’s disease
ADF = actin depolymerizing
factor
CSC2 = cardiac-speciﬁc
coﬁlin-2 knockout mouse
iDCM = idiopathic dilated
cardiomyopathy
PAO = pre-amyloid oligomers
S3A = constitutively active
coﬁlin mutant
S3E = phosphomimetic
coﬁlin mutant
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1200I n one-third of dilated cardiomyopathy(DCM) cases, the disease’s origin re-mains unknown. Consequently, for
those cases traditionally labeled “idiopathic”
(iDCM), there is no speciﬁc diagnostic test, or
targeted therapies. With the advent of a new
nomenclature for classifying cardiomyopa-
thies, patients are being grouped on the basis
of morphofunctional phenotype, involved
organ(s), genetics, and disease cause (1). Un-
der the new classiﬁcation rubric MOGES,
iDCM cases would be described as dilated
morphofunctional phenotype (M), involving
the heart (O), in sporadic cases (G) of un-known etiology (E) and classiﬁed as MDOHGSEO
(where D ¼ dilated; H ¼ heart; S ¼ sporadic; and
O ¼ no known etiology) (1).SEE PAGE 1215Myoﬁbrillar accumulation of b-sheet ﬁbrils with
structural and tintorial properties of amyloid ﬁbers,
and their precursor seeds have been recently
identiﬁed in certain iDCM hearts (2,3). They were
not related to primary amyloid systemic disorders
or to the normal aging process. With physiological
aging, aggregates derived from defective folding
or clearance of proteins accumulate as amyloid
b-sheet ﬁbrils, adversely affecting organ function
(4,5). Their premature appearance underpins nu-
merous degenerative diseases, affecting various
organs.
In the heart, the currently known illnesses due to
protein aggregates are systemic and senile amyloid-
osis or desmin and amylin cardiomyopathies. In these
conditions, the major peptides composing the ﬁbrillar
aggregates are known (monoclonal immunoglobulin
k or l light chains, wild-type [WT] or mutated trans-
thyretin, ab-crystallin or desmin, and amylin, re-
spectively). Conversely, constituents of the iDCM
aggregates and their pathogenetic role remain un-
known. A milestone in understanding the patho-
physiology of the ﬁrst disease described with protein
aggregates, Alzheimer’s disease (AD), was recog-
nizing that fragments of the amyloid precursor pro-
tein (Ab42) are the primary constituents of amyloid
plaques (6,7). Therefore, identifying the components
of the iDCM deposits is critical to understanding the
mechanisms of the disease.
In the current study, we puriﬁed the soluble car-
diac pre-amyloid seeds, which will be referred to here
as pre-amyloid oligomers (PAO), providing (to our
knowledge) the ﬁrst evidence that coﬁlin-2 is a crit-
ical component within iDCM aggregates.A 19-kDa protein, coﬁlin is a member of the ADF/
coﬁlin family of actin-binding proteins, named for its
ability to form actin ﬁlaments (COFILamentous
structures of actIN). It participates in the disassembly
of actin ﬁlaments as well as the pathogenesis of
nemaline skeletal myopathy and AD (8–10). There are
3 isoforms: coﬁlin-1, which is ubiquitously expressed;
coﬁlin-2, which is expressed mainly in muscle cells;
and destrin or ADF, which is expressed primarily in
epithelial and endothelial cells (11). Coﬁlin-1 and
coﬁlin-2 have overlapping functions and are both
present in the heart (8,10,12).
Considering its known involvement in protein
aggregate disorders in other organs such as brain
(AD) and skeletal muscle (nemaline myopathy), and
because mass spectroscopy (MS) identiﬁed coﬁlin
with its functional interactome, we focused on the
contribution of coﬁlin to the pathogenesis of iDCM.
We validated the initial discovery in a larger cohort
of human heart tissues in which we tested the
expression and activity of coﬁlin-2 and its colocali-
zation with the PAO. We then generated a cardiac-
speciﬁc coﬁlin-2 (CSC2) heterozygous knockout
mouse to model coﬁlin-2 reduced activity. The in vivo
analysis at the organ level was complemented with
in vitro measurements of contractility of isolated
cardiomyocytes to provide a better understanding of
the cellular defects caused by coﬁlin alterations.
To establish a direct causal link between the
altered pattern of coﬁlin-2 phosphorylation and sar-
comeric structure and function, we stimulated or
inhibited upstream kinases pharmacologically and
overexpressed the phosphomimetic or the constitu-
tively inactive form of coﬁlin in vitro by using
adenovirus.
METHODS
Frozen myocardial samples from the anterior wall of
the left ventricle (LV) isolated from explanted failing
hearts at the time of transplantation (MOGES desig-
nation MDOHGSE0SIV [where S refers to stage]) and
non-failing donor hearts were used to purify protein
aggregates under native conditions.
To resolve composition, we capitalized on the
common conformation of the soluble PAO and on the
availability of conformational antibodies (e.g., A11)
to immunoprecipitate them. A11s have been made to
recognize an epitope common to the conformation of
PAO rather than the unique sequence of the speciﬁc
protein forming them (13). We used MS to identify
the components of the immunoprecipitate and vali-
dated the results by immunoblotting, immunohisto-
chemistry, 2-dimensational (2D) gel electrophoresis,
TABLE 1 Clinical Parameters of Donors and iDCM Patients*
Age, yrs Sex Type Disease Associated Diseases Cause of Death Heart Weight, g FS, %
73 F Donor NA 420 60
62 BF Donor CVA 420 60
42 CM Donor Anoxic injury 320 42
57 CM Transplant iDCM AF, DM, obesity, HTN HL, HT 620 20
63 CF Transplant iDCM Anemia, AF, MVR, IDDM, HTN 330 10
53 CF Transplant iDCM Breast carcinoma, esophageal reﬂux 340 19
59 CM Transplant iDCM HTN, HL, CAD, psoriasis, gout, HT, obesity,
sleep apnea, embolic stroke
710 30
48 AM Transplant iDCM HT, VT, MR, AFl þ AV block III, PMK, PFO 393 12
*Clinical data of patients included in the initial cohort of heart samples used for PAO puriﬁcation.
AF ¼ atrial ﬁbrillation; AFl ¼ atrial ﬂutter; AM ¼ Asian male; AV ¼ atrioventricular; BF ¼ black female; CAD ¼ coronary artery disease; CF ¼ Caucasian female; CM ¼ caucasian
male; COPD ¼ chronic obstructive pulmonary disease; CRI ¼ chronic renal insufﬁciency; CVA ¼ cerebrovascular accident; DM ¼ diabetes mellitus; DO ¼ drug overdose; EF ¼
ejection fraction; ES ¼ embolic stroke; ETOH ¼ alcohol; FS ¼ fractional shortening; GSW ¼ gun shot wound; HL ¼ hyperlipidemia; HTyr ¼ hypothyroidism; HPTyr ¼ hyper-
parathyroidism; HTN ¼ hypertension; ICH ¼ intracranial hemorrhage; iDCM ¼ idiopathic dilated cardiomyopathy; IDDM ¼ insulin-dependent diabetes mellitus; LVAD ¼ left
ventricular assist device; MR ¼ mitral regurgitation; MV ¼ mitral valve; NA ¼ not available; NSVT ¼ non-sustained ventricular tachycardia; OB ¼ obesity; PE ¼ pulmonary
embolism; PHTN ¼ pulmonary hypertension; PMK ¼ pacemaker; PFO ¼ patent foramen ovale; PH¼ pulmonary hypertension; RA ¼ rheumatoid arthritis; SVT ¼ supraventricular
tachycardia; VT ¼ ventricular tachycardia.
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1201phosphate afﬁnity assay (Phos-tag), and dot blotting
analysis.
For cardiac-speciﬁc expression, Coﬁlin-2-ﬂox mice
were crossed with aMHC-Cre mice. Cardiomyocytes
were isolated from 2-month-old CSC2 mice and WT
littermates by enzymatic digestion; cultured and
analyzed as previously described (2,14). The Online
Appendix contains a detailed description of the
methods.
STATISTICAL ANALYSIS. Continuous variables were
reported as mean  SD or median (interquartileTABLE 2 Clinical Data of Patients Included in the Validation Cohort
Age, yrs Sex Type Disease Associated
58 F Donor
42 CM Donor
71 CF Donor Seizure, arthritis
56 CM Donor
65 CM Donor SVT, MV prolapse
26 CF Donor
58 CM Donor
54 CF Donor Depression
35 CM Donor
56 CM Donor
60 CM Transplant iDCM
36 M Transplant iDCM IDDM, HTN, CRI, nephro
55 CF Transplant iDCM VT, asthma, OB, PH, HTy
59 CM Transplant iDCM HTN, HL, CAD, Gout, HT
66 CM Transplant iDCM HT, CAD, HL, Gout, ETO
57 CM Transplant iDCM DM, AF, HTN, HL
63 CF Transplant iDCM Anemia, AF, MR, IDDM,
31 BF Transplant iDCM Pneumonia, asthma
65 CF Transplant iDCM AF, COPD, ETOH, HTyr
33 CF Transplant iDCM PHTN, OB, ETOH, NSVT,
19 CF LVAD Nemaline Congenital pulmonary ai
Abbreviations as in Table 1.range), as appropriate, and then compared using
Student t test or Wilcoxon rank sum test if not
normally distributed. Categorical variables were
analyzed using the Fisher exact test. Mixed effects
model was used to compare cell-derived, continuous
variables between WT and transgenic mice, using a
random effect to account for data correlation within
each mouse. Whisker lengths are covering the 5th
to 95th percentile interval. A p value of <0.05 was
considered signiﬁcant. For multiple comparison of
continuous, normally distributed data, a post hocDiseases Cause of Death Heart Weight, g FS, %
NA 353 NA
Anoxic injury 320 NA
ICH 353 NA
ICH, Trauma 400 NA
CVA, RA 458 NA
Astrocytoma 240 25
Head Trauma 486 55
DO 380 NA
GSW to head 363 55
ICH 630 76
NA 16
pathy 450 41
r, TPTyr, AF 250 22
, OB, ES 710 30
H, AF 380 20
620 20
HTN 330 10
376 10
570 10
PE, renal dysfunction 590 23
rway malformation 566 7
FIGURE 1 Coﬁlin-2 and its Substrates
Band
#
share of
spectrum id’s
Tot num
peps
Num
unique
peps
%
coverageProtein ID
60 kDa heat shock protein, mitochondrial precursor (Hsp60) (60 kDa
chaperonin) 10.10% 3 3 64.08%
Actin, alpha cardiac (Alpha-cardiac actin) 4 4 713.00% 5.18%
ATP synthase a chain (ATPase protein 6) 2 2 84.40% 1.98%
ATP synthase alpha chain, mitochondrial precursor 4 4 610.10% 4.60%
ATP synthase beta chain, mitochondrial precursor 6 6 716.40% 3.69%
Cofilin, muscle isoform (Cofilin-2) 3 3 827.10% 2.76%
Cofilin, non-muscle isoform (Cofilin-1) (18 kDa phosphoprotein) (p18) 1 1 88.40% 0.60%
Cytochrome c oxidase polypeptide II 2 2 87.50% 1.84%
Electron transfer flavoprotein alpha-subunit, mitochondrial precursor
(Alpha-ETF) 2 2 79.60% 1.10%
Gamma-interferon-inducible protein lfi-16 (Interferon-inducible myeloid
differentiation transcriptional activator) 2 2 72.40% 0.85%
Glyceraldehyde-3-phosphate dehydrogenase, liver (GAPDH) 26 30 757.30% 31.13%
Glyceraldehyde-3-phosphate dehydrogenase, muscle (GAPDH) 12 13 723.40% 10.92%
Glycogen phosphorylase, brain form 28 37 334.40% 30.66%
Guanine nucleotide-binding protein beta subunit 2-like 1 (Receptor of
activated protein kinase C 1) (RACK1) 2 2 75.00% 1.22%
Heat-shock protein beta-6 (HspB6) (Heat-shock 20 kDa like-protein p20) 4 5 862.50% 4.60%
Cardiac myosin light chain-1 (CMLC1) 2 2 814.90% 1.24%
Myosin regulatory light chain 2, ventricular\cardiac muscle isoform
(MLC-2) (MLC-2v) 3 3 819.90% 2.76%
PR-domain protein 11 2 2 11.80% 2.12%
Protein c14orf159, mitochondrial precursor (UNQ2439\PRO5000) 8 9 616.40% 12.12%
Pyridoxal kinase (Pyridoxine kinase) 2 2 76.70% 0.75%
Pyruvate dehydrogenase E1 component beta subunit, mitochondrial
precursor (PDHE1-B) 14 17 732.90% 9.31%
Stress-70 protein, mitochondrial precursor (75 kDa glucose regulated
protein) (GRP 75) 2 2 56.20% 2.51%
Succinyl-CoA ligase [GDP-forming] alpha-chain, mitochondrial precursor 2 2 79.30% 0.69%
Trifunctional enzyme alpha subunit, mitochondrial precursor (TP-alpha)
(78 kDa gastrin-binding protein) 13 16 520.20% 20.20%
iDCM A11 IP Donor A11 IPA
C
B
A11 antibody pull-down identiﬁes coﬁlin-2 and its substrates within human myocardial pre-amyloid oligomers (PAO) via electron micrographs of puriﬁed PAO from
iDCM (A) and donor (B) myocardium. PAOs are numerous in iDCM. (C) Proteins identiﬁed within PAO extracted from human tissue. ATP ¼ adenosein triphosphate;
CMLC1 ¼ cardiac myosin light chain 1; ETF ¼ electron transfer ﬂavoprotein; GAPDH ¼ glyceraldehyde-3.phosphate dehydrogenase; GRP75 ¼ glucose-related protein 75;
kDA ¼ kilodalton; pep ¼ peptides; RACK1 ¼ receptor for activated C kinase-1.
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1203analysis was performed using the Bonferroni
method. Analysis was performed using STATA data
analysis software (StataCorp LP, College Station,
Texas).
RESULTS
HUMAN SAMPLES. We previously reported detection,
characterization, and distribution of myocardial ag-
gregates positive for amyloid staining dyes in 74% of
explanted iDCM heart samples (2). From those sam-
ples, we selected 5 iDCM samples (Table 1) with the
highest presence of congophilic inclusions to isolate
the PAO and characterize their biochemical compo-
sition. Three donor hearts were used as controls. A
validation cohort consisting of 10 iDCM and 10 donor
samples (Table 2) was used to subsequently deter-
mine the expression and distribution of coﬁlin-2 in
the myocardium. Myocardial tissue was also obtained
from a patient with a diagnosis of nemaline cardio-
myopathy (Table 2).
Before acquiring the b-sheet amyloid structure,
misfolded proteins undergo progressive maturation
steps from monomers to multiple “mers-”generating
PAO (up to 24 mers). These coexist with the mature
ﬁbers in the tissues (Online Figure 1) (15–17). In this
process, proteins lose their sequence speciﬁcity and
acquire a common conformation. By using A11
conformational antibodies (13), we enriched samples
for soluble PAO from human hearts and conﬁrmed
their presence by electron microscopy (EM)
(Figures 1A and 1B).
Following immunoprecipitation, denatured PAO
components were separated by sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-
PAGE). Seven bands differentially expressed in iDCM
hearts and 1 in donor heart were excised and
analyzed by MS. Within the peptides identiﬁed in
the bands having higher expression intensity in
iDCM cases, coﬁlin-2 actin and MLC-II were present
with a high percent of coverage by MS analysis
(Figure 1C).
The expression of coﬁlin-2 in the human myocar-
dium was evaluated by SDS-PAGE. Samples were
prepared using 2 lysis buffers, one containing the
non-ionic detergent Triton-X-100, able to extract the
more soluble fraction, and one containing a high
percent of the ionic detergent SDS to extract the less
soluble aggregates. Coﬁlin-2 expression was similar in
lysates from iDCM and in donor hearts when Triton-
X-100 was used but signiﬁcantly higher in iDCM
samples than in donor myocardium in the SDS
extracts (Figure 2A). These data suggest that much of
the coﬁlin-2 in the iDCM hearts we studied is ina Triton-X-100–insoluble form. Interestingly, once
samples were plotted individually, it appeared that
coﬁlin expression in the SDS fraction was increased
in the donor hearts from older individuals (Online
Figure 2, Online Table 1).
Coﬁlin activity is regulated by reversible phos-
phorylation on Ser3. Phosphorylation inactivates and
dephosphorylation activates coﬁlin, regulating its
ability to bind G- or F-actin (Online Figure 3) (8,18–21).
The relative amount of Ser3-phosphorylated coﬁlin-2
was quantiﬁed in donor and iDCM tissue to deter-
mine howmuch of the total pool was unable to interact
with actin. Phospho-coﬁlin-2 increased signiﬁcantly
in iDCM tissue by either Triton-X-100 or SDS extrac-
tion (Figure 2B). We acknowledge the limitation of
using human heart samples that present inevitable
variability. However, differences in coﬁlin expression/
activity between iDCM and donor samples were sta-
tistically signiﬁcant despite the relatively small num-
ber of cases. We also measured the fraction of total
coﬁlin-2 that was phosphorylated by using 2D West-
ern and Phos-tag (Online Figures 4 and 5). Phos-tag
analysis conﬁrmed coﬁlin phosphorylation increased
in iDCM hearts. Finally, the amount of a-sarcomeric
actin was increased in the A11 pull-down fraction from
iDCM compared to donor hearts (Online Figure 6),
indicating that actin coprecipitates with coﬁlin in the
aggregates, validating the MS data.
To obtain further evidence of the presence of
coﬁlin-2 within PAO in the myocardium of patients
with iDCM, we stained frozen tissue sections for
A11-reactive PAO and coﬁlin-2. As shown in Figure 2C,
there was little A11 staining (Figure 2, red) in the
donor sample. Coﬁlin (Figure 2, green) did not coloc-
alize with the PAO (Figure 2C). In iDCM hearts, PAOs
were scattered within the sarcomeres in the less
damaged case (Figure 2D) and were more abundant
and clumped in larger deposits in the more damaged
case (Figure 2E, Online Figure 7). The extent of
colocalization was quantiﬁed from randomly chosen
confocal images taken from each section of the iDCM
and donor hearts using the Manders overlap coefﬁ-
cient (MOC) (22). The average MOC-M2 represents the
percentage of PAO staining colocalized with coﬁlin-2
in the region analyzed. We found that coﬁlin-2 colo-
calized with PAO in 70% of the iDCM samples we
studied but in none of the donor hearts. The calcu-
lated average M2 value was signiﬁcantly higher
in the images from iDCM than in donor samples
(p ¼ 0.000029; n ¼ 5 each group) (Figure 2F).
IN VIVO MODEL. The results in human specimens
suggest that a loss in coﬁlin-2 actin-binding activity
may have important implications in cardiac structural
FIGURE 2 Coﬁlin-2 Prominence in iDCM PAO
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FIGURE 2 Continued
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(A) Expression of total coﬁlin-2 in donor (blue bars) and iDCM (salmon bars) human hearts following extraction with Triton X-100 (left panels) or sodium dodecyl
sulfate (SDS) detergents (right panels). Coﬁlin-2 quantity is increased in iDCM with SDS detergent. *p < 0.05. (B) Phospho-coﬁlin-2 increased signiﬁcantly in iDCM by
Triton-X-100 and SDS extraction. *p < 0.05; **p < 0.01. Values are means  SD; sample numbers are indicated in the bars. (C) Colocalization of coﬁlin-2 and PAO in
donor and (D to E) iDCM hearts. Pixel intensity and distance overlap in iDCM but not in donor hearts; boxes deﬁne areas at higher magniﬁcation. Coﬁlin-2, green;
A11-stained PAO, red; nuclei stained with 4’,6-diamidino-2-phenylindole (DAPI) are shown in blue. (D) iDCM sample with less A11-positive PAOs. Here, A11 stain
colocalizes in the area of coﬁlin still within sarcomeres. (E) iDCM sample with more abundant PAOs clustered in larger aggregates (more examples are shown in Online
Figure 7). (F) Colocalization was quantiﬁed by Manders correlation coefﬁcient (M). M1 represents the percent of colocalization of coﬁlin-2 with the PAO; M2 represents
colocalization of PAOs with coﬁlin-2; M2 Manders coefﬁcient was calculated from multiple random images collected from 5 donor and 5 iDCM hearts. p ¼ 0.000029.
Values in each sample were pooled and averaged. Open symbols are individual samples; solid symbols are mean values for donor (blue) and iDCM (orange) hearts.
GAPDH ¼ glyceraldehyde 3-phosphate dehydrogenase; MW ¼ molecular weight. Other abbreviations as in Figure 1.
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1205and functional disarray found in iDCM with protein
aggregates. However, the assays possible in human
hearts are limited. Although severe inactivation or
depletion of coﬁlin causes early onset myopathy in
skeletal muscle, our series of cases consisted of adult
onset iDCM, where the inactivation of coﬁlin by
phosphorylation was incomplete. This poses the
question of whether a partial defect in coﬁlin activity
would contribute to development of contractile
dysfunction and cardiac muscle myopathy. Hence, wecreated a mouse model of cardiac-speciﬁc coﬁlin-2
haploinsufﬁciency (CSC2).
Compared to their WT littermates, heterozygous
CSC2 mice showed a 60% reduction in coﬁlin-2
expression (Figure 3A). Using echocardiography, we
observed 2-month-old CSC2mice alreadymanifested a
marked decrease in LVwall thickness, ejection fraction
(EF), and fractional shortening (FS), as well as
increased LV end-diastolic diameter (LVEDD) and LV
end-systolic diameter (LVESD) (Figures 3B to 3D,
FIGURE 3 Coﬁlin-2 Expression and Cardiac Phenotype in CSC2 Haploisufﬁcient Mice
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Continued on the next page
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1206Online Figure 8). The statistical signiﬁcance of the
echocardiographic data was conﬁrmed by Bonferroni
post-hoc analysis (Online Appendix). At this stage,
interstitial ﬁbrosis was not detected (Online Figure 9).
Myoﬁbrils were altered in CSC2 animals showing
abnormal actin pattern, a lack of proper orientation,
and poorly organized sarcomeres as revealed by
immunohistochemistry (Figure 3G) and EM (Figures 3J
and 3L, inset 2, Online Figure 10). The I and M bands
were frequently absent in sarcomeres, which were
often hypercontracted, and the Z lineswere interrupted
(Figure 3J, inset 2 and arrowheads). Mice also displayed
structures similar to actin rods described in nemalinemyopathy (23) (Figures 3J and 3L, inset 1). Notably, we
observed by EM that the pathological features of the
CSC2 mice myocardium closely recapitulated the
pathology shown in a case of human nemaline
cardiomyopathy (Figure 3K, Online Figure 10).
The morphological defects of the myocardium of
CSC2 mice were accompanied by abnormalities in cell
function. In comparison with WT cardiomyocytes,
CSC2 cardiomyocytes showed a prolongation in cell
shortening and Ca2þ transient velocities (Figure 4,
Table 3).
Knockout mouse models have previously served
well to model the biological and pathological effect
FIGURE 3 Continued
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1207of a prevalent inactive coﬁlin-1 (24,25). However, the
coﬁlin/actin ratio may also modulate formation of
actin bundles and rods, thus affecting the sarcomeric
machinery structure and function (10). Therefore, we
determined the impact of altered patterns of coﬁlin-2
phosphorylation on cardiomyocyte structure andfunction by pharmacologic manipulation of coﬁlin
upstream signaling and genetic modulation of coﬁlin
phosphorylation.
Coﬁlin-1 and -2 are phosphorylated on Ser3 by LIM-
domain kinase (LIMK) and TES kinase (TESK); both
are downstream of the Ras-homolog gene family
FIGURE 4 Reduced Velocities of Rise and Decline of Ca2þ Transients in CSC2 Cardiomyocytes
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Box plots of Ca2þ transient peak and return velocity times expressed as a Fura-2 ratio of 340:380 (Ra peak t and Ra ret v t) and nM Ca2þ (Ca2þ
peak t and Ca2þ ret v t). Isolated cardiomyocytes from CSC2 mice show signiﬁcantly slower transient parameters. Measurements were obtained
from 31 cells from 4 WT littermate mice (blue boxes), and 14 cells from 2 CSC2 mice (salmon boxes). Mixed model statistical analysis was
applied to allow statistical analysis of 2 CSC2 mice. *p < 0.05; #p < 0.005; data are means  SD. Abbreviations as in Figure 3.
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1208member A (RhoA) and the Rho-associated protein-
kinase (ROCK) (Online Figure 11) (18). RhoA stimula-
tion signiﬁcantly increased the phosphorylation
levels of coﬁlin-2 and led to the formation of
“stress-like” ﬁbers in adult mice cardiomyocytes
(p < 0.05) (26). Conversely, “stress-like” ﬁbers were
not observed with inhibition of ROCK that reduced
coﬁlin-2 phosphorylation (although the p value did
not reach statistical signiﬁcance; p ¼ 0.09) (Figures 5A
and 5B).
Because pharmacological stimulation may lead to
speciﬁcity issues with dosing, we used an adenoviral
(Ad.) gene transfer approach to express the phos-
phomimetic (Ad.S3E), constitutively active (Ad.S3A),
and WT form of coﬁlin-1 in neonatal rat car-
diomyocytes (Figure 6). Compared to adenoviral
overexpression levels of WT or S3A, only Ad.S3E
induced the formation of “stress-like” ﬁbers in car-
diomyocytes (Figure 6C). Overexpressing the phos-
phomimetic form of coﬁlin-2 (Ad.S3E) abrogatedcontractile function and impaired survival of adult
cardiomyocytes, impeding functional measurement.
DISCUSSION
Lack of knowledge regarding the mechanisms that
initiate the myocardial defect in iDCM is the critical
barrier to early screening and prevention, and ulti-
mately to a cure for this devastating disease. The
recent discovery of the presence in iDCM of plaque-
and tangle-like aggregates that impair cell function
in cardiomyocytes (2,3) identiﬁes a new patho-
genesis for at least some cases. However, the aggre-
gates’ composition, which has contributed to the
understanding of the pathogenesis and consequently
progress toward new AD therapies, is a critical but
unresolved issue in the pathogenesis of iDCM.
Our study demonstrates that the actin-
depolymerizing protein coﬁlin-2, along with its inter-
acting proteins actin and MLC-II, are incorporated
TABLE 3 Cardiomyocyte Contractility and Ca2þ Transient Parameters:
Slower Contraction and Relaxation Velocities
Parameter
WT CSC2
p ValueAverage SD Average SD
Cell length
Dep v t, s 0.017 0.005 0.019 0.007 0.240
Bl%peak h 2.813 2.808 2.731 2.571 0.890
Peak t, s 0.044 0.011 0.048 0.012 0.330
Ret v t, s 0.066 0.020 0.072 0.021 0.480
T to bl 50.0% 0.076 0.020 0.078 0.022 0.770
T to bl 90.0% 0.122 0.032 0.107 0.020 0.400
Sin exp tau, s 0.049 0.025 0.043 0.022 0.640
Sarcomere length
Dep v t, s 0.018 0.005 0.023 0.009 0.040
Bl%peak h 0.047 0.037 0.064 0.052 0.630
Peak t, s 0.045 0.009 0.053 0.014 0.045
Ret v t, s 0.068 0.017 0.078 0.022 0.160
T to bl 50.0% 0.076 0.018 0.084 0.024 0.270
T to bl 90.0% 0.124 0.025 0.112 0.029 0.300
Sin exp tau, s 0.047 0.023 0.048 0.019 0.850
F0/F1 ratio
Bl 1.923 0.290 1.710 0.159 0.120
Dep v t, s 0.008 0.004 0.009 0.004 0.500
Peak 2.858 0.589 2.542 0.282 0.410
Peak t, s 0.023 0.005 0.030 0.008 0.003
Ret v t, s 0.059 0.018 0.077 0.024 0.008
T to bl 50.0% 0.079 0.017 0.084 0.012 0.590
T to bl 90.0% 0.136 0.033 0.144 0.017 0.800
Sin exp tau, s 0.107 0.038 0.232 0.436 0.100
Calcium
Bl, nM 303.753 78.286 308.103 52.351 0.850
Dep v t, s 0.008 0.003 0.009 0.004 0.280
Peak, nM 617.551 298.323 610.833 111.381 0.970
Peak t, s 0.023 0.005 0.030 0.007 0.005
Ret v t, s 0.058 0.017 0.072 0.027 0.030
T to bl 50.0% 0.077 0.016 0.086 0.010 0.280
T to bl 90.0% 0.136 0.031 0.145 0.011 0.570
Sin exp tau, s 0.105 0.039 0.108 0.027 0.740
Contractile parameters from the whole cell length, sarcomere shortening, and Ca2þ transient measured as
Fura-2 ratio and nM Ca2þ. Signiﬁcant p values are indicated in bold type.
Bl ¼ diastolic Ca2þ levels; Bl%peak h ¼ cell shortening expressed as % of resting length; CSC2 ¼ cardiac-
speciﬁc coﬁlin-2 mice; Dep v t ¼ departure velocity time; Peak ¼ systolic Ca2þ levels; Peak t ¼ time to peak;
Ret v t ¼ return velocity time; Sin exp tau ¼ index of isovolumic relaxation; t to bl 50.0% and t to bl 90.0% ¼
times to 50% and 90% relaxation times; WT ¼ wild-type mice.
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1209within the iDCM aggregates. In most of our human
iDCM samples, coﬁlin-2 expression was increased, and
most were found within the aggregates recognized by
the A11 structural antibody (Central Illustration).
Moreover, coﬁlin-2 activity in iDCM tissue was
decreased owing to its enhanced degree of phos-
phorylation. Together, coﬁlin-2 sequestration in the
aggregates and inactivation by enhanced phosphory-
lation will interfere with its critical function
in maintaining actin ﬁlament homeostasis, affecting
myocyte contractility.
Coﬁlin contributes to the dynamic turnover of
actin composing the thin ﬁlaments in contractile
cells and microﬁlaments in non-contractile cells (10).
Consequently, coﬁlin is an essential protein that
maintains the myoﬁlament architecture needed
for the mechanical properties of sarcomeres, cell
motility, and intracellular transport (8,10,27). Abnor-
malities at this level will critically hamper car-
diomyocyte function, as was shown for skeletal
myocytes and neurons. In fact, coﬁlin is thought
to be involved in the pathogenesis of neurodegener-
ative diseases (including corticobasal degeneration,
William’s syndrome, fragile X syndrome, and
spinal muscular atrophy), and skeletal muscle myo-
pathy, where it accumulates as coﬁlin/actin rods
(9,23,28,29). Consistent with these ﬁndings, the
presence of coﬁlin-2, actin, and MLC-II in the PAO-
enriched lysate in iDCM points toward similar struc-
tures forming in cardiomyocytes. Interestingly, the
differences between coﬁlin sequestration in iDCM
hearts and that in donor hearts were reduced with
age. These data are consistent with the hypothesis
that iDCM, like AD, is a pathology bearing an antici-
pated aging phenotype.
Functionally, coﬁlin regulation of actin dynamics
is controlled by reversible phosphorylation. Coﬁlin
phosphorylation on Ser3 by TESK or LIMK inactivates,
and dephosphorylation by “slingshot” or chronophin
phosphatases activates coﬁlin to bind either
G- or F-actin (18). Consequently, the proper balance
of phosphorylated/dephosphorylated coﬁlin is re-
quired for cytoskeleton organization, sarcomeric ho-
meostasis, and contractile function. Here we add
pristine evidence of unbalanced coﬁlin-2 phosphory-
lation in iDCM heart samples. Lack of coﬁlin activity
would lead to the accumulation of polymerized
F-actin ﬁlaments and impaired contractility, as
shown here, either directly by pharmacological stim-
ulation of coﬁlin phosphorylation and by genetic
expression of the phosphomimetic coﬁlin mutant
in cardiomyocytes or indirectly by means of the
CSC2 mouse model. In vitro cardiomyocyte pharma-
cological stimulation of the endogenous proteinphosphorylation resulted in ﬁbrillar accumulation.
Likewise, genetic expression of human phosphomi-
metic coﬁlin generated “stress-like” ﬁbers and
hampered cardiomyocyte contractility. The mouse
model of cardiac-speciﬁc coﬁlin-2 haploinsufﬁciency
aptly recapitulated the human cardiac phenotype.
Disorganized myoﬁbrils, immature hypercontracted
sarcomeres and aggregates, and disruption of the
Z-bands, typical of nemaline myopathic skeletal
and cardiac muscle, were apparent in CSC2 car-
diomyocytes, accounting for a decline in these cells’
contribution to cardiac function. Indeed, the coexis-
tence of intact and disrupted sarcomeres can be
FIGURE 5 Pharmacological Phosphorylation of Coﬁlin-2 Induces Formation of Stress-Like Fibers in Cardiomyocytes
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(A) Phosphorylation of coﬁlin-2 is increased after stimulation of RhoA (salmon bars) (*p < 0.05) and is reduced by ROCK inhibition (black bars) compared to that of
control vehicle (blue bars); values are means  SD; numbers of samples are shown in the bars. MW ¼molecular weight; kDa ¼ kilodalton. (B) RhoA stimulation and ROCK
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phalloidin staining of F-actin; red, phospho-coﬁlin; blue, nuclei stained with DAPI. RhoA ¼ Ras-homolog gene family member A; ROCK ¼ Rho-associated-protein-kinase.
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1210expected to interfere with sarcomere mechanics,
affecting cardiac function.
In vitro modulation of coﬁlin activity and
the structural abnormalities developed in the CSC2
mouse may not entirely reproduce the pathological
changes found in human iDCM. Likewise, coﬁlin ab-
normalities may not represent the pathogenetic fac-
tor in all cases of iDCM. However, the pathology ofthe CSC2 mouse myocardium recapitulates the pa-
thology of human nemaline (cardio)myopathy, and
coﬁlin may participate in the pathogenesis of iDCM
in a subgroup of patients, as is the case of other
amyloid-related cardiomyopathies. Additional large-
scale studies are warranted to determine how many
cases of iDCM with amyloid-like aggregates have
coﬁlin-2 defects as a pathological substrate.
FIGURE 6 Genetic Overexpression of Phosphomimetic Ser3-Coﬁlin-2 Induces Formation of Stress-Like Fibers in Cardiomyocytes
(A) WT coﬁlin-1, (B) Ad.S3A (constitutively active), or (C) Ad.S3E (phosphomimetic) infected neonatal cardiomyocytes. Adenoviral expression of the phosphomimetic
coﬁlin-1 increased the formation of “stress-like” ﬁbers (arrowheads). Red-ﬂuorescence-protein reporter (RFP) gene indicates cardiomyocytes infected with Ad.WT,
Ad.S3A, or Ad.S3E, red; a-sarcomeric actin, green; phalloidin staining of F-actin, teal; nuclei stained with DAPI, blue.
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1211Notably, active coﬁlin competitively inhibits
myosin-II binding to F-actin, and loss of this modu-
latory mechanism in coﬁlin-depleted cells increases
myosin-II/actin assembly, leading to further accu-
mulation of abnormal F-actin (30). Interestingly, both
actin and MLC-II were found to be enriched in cardiac
PAO. Thus, in addition to the effects of loss of
coﬁlin-2 function on actin, changes in the amount of
MLC-II could contribute to disorganization of the
contractile apparatus, further impairing car-
diomyocyte function (2,27,31). Furthermore, by
accumulating in PAO, coﬁlin-2, actin, and MLC-II will
alter myocardial function through PAO direct toxicity.
Hence, coﬁlin pathology may alter myocardial
contractility by a triple mechanism: “aggregate-independent” loss of function of the sequestered
sarcomeric protein(s); “aggregate-dependent” gain of
PAO toxicity; and mechanical disruption of sarco-
meric integrity, as previously shown for other
misfolded-prone proteins (2,32).
In addition to contractility, coﬁlin has essential
functions in other actin-related cellular processes,
including trafﬁcking of intracellular molecules,
directional motility, cell division, and viability
(10,33). As a main structural component of the cyto-
skeletal network, actin also organizes receptors
through interactions on the cytosolic side of the cell
membrane, mediating intracellular signaling in
response to extracellular matrix deformation and
mechanical stress. Furthermore, the upstream
CENTRAL ILLUSTRATION Coﬁlin in Cardiac Plaques: New Mechanisms for Dilated Cardiomyopathy
Plaque- and tangle-like aggregates accumulate in the myocardium in some cases of idiopathic dilated cardiomyopathy (iDCM). The actin depolymerizing protein coﬁlin is
enriched in the aggregates, together with its binding partners actin and MHCII. Coﬁlin is for the most part phosphorylated and thus inactivated in iDCM. The prevalent
inhibition of coﬁlin activity in conjunction with damage to the myoﬁbrillar integrity and the accumulation of ﬁbrillar aggregates interfere with the proper function of the
sarcomeres ultimately contributing to cardiac dysfunction in these cases of iDCM. A11 ¼ structural antibody; P ¼ phosphorylation.
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1212regulator of coﬁlin activity, RhoA, cooperatively co-
ordinates cell migration and motility with the small
GTPase RhoA subfamily member Rac. Their reciprocal
functions in mediating cytoskeletal plasticity may
regulate cell geometry and rigidity in response to
extracellular stress and force generation (34). Finally,
actomyosin dynamic polymerization coordinates the
appropriate distribution of the duplicated chromo-
somes during cytokinesis (27,30,31,35,36). Thus,
abnormalities in coﬁlin regulation of actin networks
may also negatively affect the replicating capacity,
shaping, and maturing of the developing heart. At
the same time, although not univocally accepted
(24,37), when in its active form, coﬁlin promotes
the translocation of Bax to the mitochondria, trig-
gering the cell death pathway. This process of cellclearance is impaired in the presence of increased
phospho-coﬁlin-2, interfering with its beneﬁcial ef-
fects on cellular survival and aging. Thus, changes
in normal coﬁlin pattern may further contribute to
the development of cardiomyopathy by affecting
tissue remodeling and impairing the myocardial
ability to respond to stress.
STUDY LIMITATIONS. We acknowledge the limitation
of using human heart samples that present inevitable
variability. We minimized the variability by matching
the samples at best for age, sex, and ethnicity be-
tween iDCM and control samples. We acknowledge
the differences in structural appearance of the stress-
like and the rod-like structures, which warrant
further studies.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The actin-
depolymerizing protein coﬁlin occurs in the cellular aggregates in
nemaline skeletal myopathy and Alzheimer’s disease, and in
recently identiﬁed aggregates in patients with iDCM. This
suggests a common pathogenic mechanism linking inactivation
and sequestration of coﬁlin in cerebral and skeletal muscle
and cardiac tissue.
TRANSLATIONAL OUTLOOK: In the new classiﬁcation,
MOGES(1), an additional etiological category for the dilated
morphofunctional phenotype (M) could be included as EA-C:
coﬁlin-type. Whether other organs, other than the heart, would
be involved, these cases could be classiﬁed as MDOHþBþ
MGSEA-C. An immediate translational implication of the ﬁndings
is the possibility that patients with this form of iDCM may have
organ alterations more diffuse than originally anticipated.
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1213Whether coﬁlin appears to provide a new patho-
genetic mechanism for iDCM, its primary role in the
development of iDCM could not be proven in the
human samples, as presently there are no known
mutations in coﬁlin human gene (CFL) leading to
iDCM.
CONCLUSIONS
Our study demonstrates that coﬁlin-2 and its inter-
actome are present in human and experimental
myocardial aggregates and that abnormalities in this
protein complex alter myocyte structure and func-
tion. Moreover, coﬁlin-2 activity is decreased in
iDCM tissue due to its enhanced degree of phos-
phorylation. Therefore, coﬁlin-2 sequestration in
aggregates, in tandem with its inactivation, is likely
to interfere with critical coﬁlin-2 functions in the
maintenance of actin ﬁlament homeostasis for
effective myocyte contraction and relaxation. Thus,
abnormal coﬁlin regulation provides a novel patho-
genetic mechanism for iDCM and a novel conceptual
ground for future development of personalized
therapies.
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APPENDIX For an expanded Methods section
as well as supplemental ﬁgures and a table,
please see the online version of this article.
